Rivoceranib-Camrelizumab

Elevar Therapeutics, Rivoceranib-Camrelizumab, Liver Cancer, FDA

Elevar Therapeutics Announces FDA Acceptance of Rivoceranib-Camrelizumab Combo for Liver Cancer

SG Tylor

On July 17, 2023  Elevar Therapeutics, a fully integrated biopharmaceutical company focused on improving treatment options for patients with limited ...